Aurobindo Pharma's Eugia Unit-3 gets warning letter from USFDA, shares fall

Aurobindo Pharma's subsidiary Eugia Pharma Specialities received a warning letter from the USFDA concerning its formulations manufacturing unit in Telangana. This followed an earlier inspection that resulted in an 'Official Action Indicated' status. Aurobindo affirmed that current US supplies are unaffected and emphasized their commitment to enhancing compliance with regulatory standards.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9jPg7Sa
via IFTTT